Invictus MD Strategies Competitors

Abacus Health Products (OTCMKTS:ABAHF) and Invictus MD Strategies (OTCMKTS:IVITF) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Abacus Health Products and Invictus MD Strategies, as provided by MarketBeat.

Profitability

This table compares Abacus Health Products and Invictus MD Strategies' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Abacus Health Products and Invictus MD Strategies' revenue, earnings per share (EPS) and valuation.

Acreage (OTCMKTS:ACRGF) and Invictus MD Strategies (OTCMKTS:IVITF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation and Earnings

This table compares Acreage and Invictus MD Strategies' revenue, earnings per share and valuation.

Profitability

This table compares Acreage and Invictus MD Strategies' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations for Acreage and Invictus MD Strategies, as reported by MarketBeat.

Acreage presently has a consensus target price of $8.4333, indicating a potential upside of 204.45%. Given Acreage's higher probable upside, equities research analysts clearly believe Acreage is more favorable than Invictus MD Strategies.

Summary

Acreage beats Invictus MD Strategies on 2 of the 2 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and Invictus MD Strategies (OTCMKTS:IVITF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent recommendations for Applied Biosciences and Invictus MD Strategies, as reported by MarketBeat.

Valuation and Earnings

This table compares Applied Biosciences and Invictus MD Strategies' revenue, earnings per share and valuation.

Profitability

This table compares Applied Biosciences and Invictus MD Strategies' net margins, return on equity and return on assets.

Invictus MD Strategies (OTCMKTS:IVITF) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Earnings & Valuation

This table compares Invictus MD Strategies and Ayr Strategies' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Invictus MD Strategies and Ayr Strategies, as reported by MarketBeat.

Ayr Strategies has a consensus target price of $34.8571, indicating a potential upside of 63.96%. Given Ayr Strategies' higher probable upside, analysts plainly believe Ayr Strategies is more favorable than Invictus MD Strategies.

Profitability

This table compares Invictus MD Strategies and Ayr Strategies' net margins, return on equity and return on assets.

Summary

Ayr Strategies beats Invictus MD Strategies on 2 of the 2 factors compared between the two stocks.

Invictus MD Strategies (OTCMKTS:IVITF) and Can B (NASDAQ:CANB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations.

Earnings and Valuation

This table compares Invictus MD Strategies and Can B's top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Invictus MD Strategies and Can B, as reported by MarketBeat.com.

Profitability

This table compares Invictus MD Strategies and Can B's net margins, return on equity and return on assets.

Cansortium (OTCMKTS:CNTMF) and Invictus MD Strategies (OTCMKTS:IVITF) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Earnings & Valuation

This table compares Cansortium and Invictus MD Strategies' gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Cansortium and Invictus MD Strategies' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and price targets for Cansortium and Invictus MD Strategies, as provided by MarketBeat.

Cansortium currently has a consensus price target of $1.20, indicating a potential upside of 43.13%. Given Cansortium's higher probable upside, research analysts clearly believe Cansortium is more favorable than Invictus MD Strategies.

Summary

Cansortium beats Invictus MD Strategies on 2 of the 2 factors compared between the two stocks.